89Bio Inc
NASDAQ:ETNB
89Bio Inc
Research & Development
89Bio Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
89Bio Inc
NASDAQ:ETNB
|
Research & Development
-$421m
|
CAGR 3-Years
-71%
|
CAGR 5-Years
-70%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
89Bio Inc
Glance View
89bio, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in San Francisco, California and currently employs 41 full-time employees. The company went IPO on 2019-11-11. The firm is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The firm's lead product candidate, BIO89-100, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). FGF21 is a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism. The firm's subsidiaries include 89Bio Ltd, 89bio Management, Inc. and UAB 89bio Lithuania.
See Also
What is 89Bio Inc's Research & Development?
Research & Development
-421m
USD
Based on the financial report for Jun 30, 2025, 89Bio Inc's Research & Development amounts to -421m USD.
What is 89Bio Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-70%
Over the last year, the Research & Development growth was -168%. The average annual Research & Development growth rates for 89Bio Inc have been -71% over the past three years , -70% over the past five years .
